Abstract 1652P
Background
Obesity amplifies the risk for various cancers, including pancreatic cancer (PC). Due to limited early screening methods, this study seeks to investigate the effects of obesity-related metabolic disorders on PC initiation and offer novel insights into early detection and diagnosis in obese populations.
Methods
Human pancreatic Nestin-expressing ductal cells (HPNE) were cultured with human serum obtained from obese patients and healthy individuals. Transcriptomics, untargeted metabolomics, and joint-pathway analyses were conducted to examine the impacts of obesity-related metabolic disorders on pancreatic carcinogenesis. Multiomics analysis results were validated using cells of varying genetic backgrounds, while their mechanisms and roles in PDAC development were explored in obese transgenic mouse models. Clinical relevance and translational value were also corroborated using public databases and human samples.
Results
Multiomic assessment revealed heightened cytokine signalling and ferroptosis defence in HPNE cells exposed to obesity serum. In vitro tests showed that upregulated interleukin 34 (IL-34) strengthens ferroptosis defence through oxidative stress, while the enhanced ferroptosis defence reciprocally raises IL-34 levels. Our study demonstrated that augmented IL-34 signalling and ferroptosis defence hasten PDAC initiation in diet-induced obese mice by increasing immunosuppressive macrophages infiltration. Public databases revealed a strong correlation between elevated IL-34 and glutathione peroxidase 4 (GPX4) expression in pancreatic tumors vs. normal tissues. Gene signature expression displayed substantial correlations as well. Cohort validation and single-cell analysis suggested a positive association between IL-34 signalling and ferroptosis defence enhancement with PDAC patients' body mass index (BMI).
Conclusions
Obesity elevates IL-34 signalling and ferroptosis defence, thereby promoting PDAC development via macrophage-induced immunosuppression. The observed positive correlations between IL-34 and BMI, as well as GPX4 and BMI in PDAC patients underscore their potential roles in early PC screening among the obese population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This project received funding from the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS, 2021-I2M-1-002), National High Level Hospital Clinical Research Funding (2022-PUMCH-D-001), National Multidisciplinary Cooperative Diagnosis and Treatment Capacity Building Project for Major Diseases, National Natural Science Foundation of China (NSFC, 81970763), Foundation Project for Young Scientists of NSFC (82102810), the Fellowship of China Postdoctoral Science Foundation (2021M700501), the Postdoctoral ScienceFoundation of Peking Union Medical College Hospital (2022T150067), and the Non-profit Central Research Institute Fund of CAMS (2018PT32014).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1579P - Gender differences and worse metastatic survival outcomes in young adult patients with oesophagogastric cancer: 12-year data from a Czech comprehensive cancer center
Presenter: Tomás Sokop
Session: Poster session 22
1580P - Early onset oesophageal adenocarcinoma: A separate biological entity?
Presenter: Dharmesh Valand
Session: Poster session 22
1581P - Total neoadjuvant chemotherapy with FOLFIRINOX regimen in patients with resectable locally advanced gastric and gastroesophageal junction cancer
Presenter: Maria Sedova
Session: Poster session 22
1582P - Gastroesophageal adenocarcinoma in young adults: Retrospective analysis of clinical and molecular features
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1583P - Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: A systematic review and meta-analysis
Presenter: Niels Guchelaar
Session: Poster session 22
1585P - The impact of platinum-induced peripheral neuropathy (PN) in first-line treatment on PN and efficacy in second-line paclitaxel (PTX)-based chemotherapy for unresectable advanced gastric cancer (AGC): A prospective observational multicenter study - IVY study
Presenter: Yoshiyasu Kono
Session: Poster session 22
1587P - Analysis of survival outcomes according to start timing of adjuvant chemotherapy in patients with gastric cancer: A retrospective nationwide cohort study
Presenter: Tae-Hwan Kim
Session: Poster session 22
1588P - Analysis of risk factors of anastomotic leakage after minimally invasive esophagectomy with circular cervical anastomosis
Presenter: ming lu
Session: Poster session 22